Journal of Molecular and Cellular Cardiology
Volume 48, Issue 3 , Pages 497-503 , March 2010

Renal studies provide an insight into cardiac extracellular matrix remodeling during health and disease

  • Alexandre Hertig

      Affiliations

    • Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, USA
    • ,
  • Taduri Gangadhar

      Affiliations

    • Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, USA
    • ,
  • Raghu Kalluri

      Affiliations

    • Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, USA
    • Department of Biological Chemistry and Molecular Pharmacology, USA
    • Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA
    • Corresponding Author InformationCorresponding author. Department of Medicine, Harvard Medical School, Division of Matrix Biology. Center for Life Sciences, #11-086, Beth Israel Deaconess Medical Center, 3 Blackfan Circle, Boston, MA 02115, USA. Tel.: +1 617 735 4601; fax: +1 617 735 4602.

Received 7 June 2009 ,Revised 2 July 2009 ,Accepted 18 July 2009.

References 

  1. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J. Am. Coll. Cardiol. 2008;52:1527–1539
  2. Berl T, Henrich W. Kidney–heart interactions: epidemiology, pathogenesis, and treatment. Clin. J. Am. Soc. Nephrol. 2006;1:8–18
  3. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med. 2004;351:1285–1295
  4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004;351:1296–1305
  5. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J. Am. Soc. Nephrol. 2003;14:1132–1144
  6. Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system: implications in cardiovascular remodeling. Curr. Opin. Nephrol. Hypertens. 2008;17:168–173
  7. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 1992;327:669–677
  8. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N. Engl. J. Med. 1996;334:1448–1460
  9. Humar A, Ramcharan T, Kandaswamy R, Gillingham K, Payne WD, Matas AJ. Risk factors for slow graft function after kidney transplants: a multivariate analysis. Clin. Transplant. 2002;16:425–429
  10. Lindsey ML. MMP induction and inhibition in myocardial infarction. Heart. Fail. Rev. 2004;9:7–19
  11. Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J. Clin. Invest. 2002;110:1525–1538
  12. Kassiri Z, Oudit GY, Kandalam V, Awad A, Wang X, Ziou X, et al. Loss of TIMP3 enhances interstitial nephritis and fibrosis. J. Am. Soc. Nephrol. 2009;20:1223–1235
  13. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 2009;
  14. Preston RA, Epstein M. Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J. Hypertens. 1997;15:1365–1377
  15. Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, et al. Acute kidney injury increases risk of ESRD among elderly. J. Am. Soc. Nephrol. 2009;20:223–228
  16. Zeisberg M, Strutz F, Muller GA. Role of fibroblast activation in inducing interstitial fibrosis. J. Nephrol. 2000;13(Suppl 3):S111–120
  17. Neilson EG. Mechanisms of disease: fibroblasts—a new look at an old problem. Nat. Clin. Pract. Nephrol. 2006;2:101–108
  18. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial–mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest. 2009;119:1438–1449
  19. Zeisberg M, Neilson EG. Biomarkers for epithelial–mesenchymal transitions. J. Clin. Invest. 2009;119:1429–1437
  20. Zeisberg M, Bottiglio C, Kumar N, Maeshima Y, Strutz F, Muller GA, et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am. J. Physiol. Renal. Physiol. 2003;285:F1060–1067
  21. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 2002;110:341–350
  22. Kalluri R, Weinberg RA. The basics of epithelial–mesenchymal transition. J. Clin. Invest. 2009;119:1420–1428
  23. Rastaldi MP, Ferrario F, Giardino L, Dell'Antonio G, Grillo C, Grillo P, et al. Epithelial–mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney. Int. 2002;62:137–146
  24. Vongwiwatana A, Tasanarong A, Rayner DC, Melk A, Halloran PF. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am. J. Transplant. 2005;5:1367–1374
  25. Hertig A, Verine J, Mougenot B, Jouanneau C, Ouali N, Sebe P, et al. Risk factors for early epithelial to mesenchymal transition in renal grafts. Am. J. Transplant. 2006;6:2937–2946
  26. Hertig A, Anglicheau D, Verine J, Pallet N, Touzot M, Ancel PY, et al. Early epithelial phenotypic changes predict graft fibrosis. J. Am. Soc. Nephrol. 2008;19:1584–1591
  27. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 2007;13:952–961
  28. Neilson EG. Plasticity, nuclear diapause, and a requiem for the terminal differentiation of epithelia. J. Am. Soc. Nephrol. 2007;18:1995–1998
  29. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell. Biol. 2004;5:343–354
  30. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Invest. 2007;117:3810–3820
  31. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J. Am. Soc. Nephrol. 2006;17:17–25
  32. Sampson NS, Ryan ST, Enke DA, Cosgrove D, Koteliansky V, Gotwals P. Global gene expression analysis reveals a role for the alpha 1 integrin in renal pathogenesis. J. Biol. Chem. 2001;276:34182–34188
  33. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, et al. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature. 1996;379:91–96
  34. Hu K, Wu C, Mars WM, Liu Y. Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling. J. Clin. Invest. 2007;117:3821–3832
  35. Hu K, Lin L, Tan X, Yang J, Bu G, Mars WM. tPA protects renal interstitial fibroblasts and myofibroblasts from apoptosis. J. Am. Soc. Nephrol. 2008;19:503–514
  36. Edgtton KL, Gow RM, Kelly DJ, Carmeliet P, Kitching AR. Plasmin is not protective in experimental renal interstitial fibrosis. Kidney. Int. 2004;66:68–76
  37. Luttun A, Lupu F, Storkebaum E, Hoylaerts MF, Moons L, Crawley J, et al. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2002;22:499–505
  38. Hertig A, Berrou J, Allory Y, Breton L, Commo F, Costa De Beauregard MA, et al. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. Faseb. J. 2003;17:1904–1906
  39. Gaertner R, Jacob MP, Prunier F, Angles-Cano E, Mercadier JJ, Michel JB. The plasminogen-MMP system is more activated in the scar than in viable myocardium 3 months post-MI in the rat. J. Mol. Cell. Cardiol. 2005;38:193–204
  40. Hahm K, Lukashev ME, Luo Y, Yang WJ, Dolinski BM, Weinreb PH, et al. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am. J. Pathol. 2007;170:110–125
  41. Rinn JL, Bondre C, Gladstone HB, Brown PO, Chang HY. Anatomic demarcation by positional variation in fibroblast gene expression programs. PLoS. Genet. 2006;2:e119
  42. Hannigan GE, Coles JG, Dedhar S. Integrin-linked kinase at the heart of cardiac contractility, repair, and disease. Circ. Res. 2007;100:1408–1414
  43. Shai SY, Harpf AE, Babbitt CJ, Jordan MC, Fishbein MC, Chen J, et al. Cardiac myocyte-specific excision of the beta1 integrin gene results in myocardial fibrosis and cardiac failure. Circ. Res. 2002;90:458–464
  44. Lin J, Patel SR, Cheng X, Cho EA, Levitan I, Ullenbruch M, et al. Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat. Med. 2005;11:387–393
  45. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 2003;9:964–968
  46. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J. Biol. Chem. 2007;282:23337–23347
  47. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. 1998;339:69–75
  48. Assmus B, Honold J, Schachinger V, Britten MB, Fischer-Rasokat U, Lehmann R, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N. Engl. J. Med. 2006;355:1222–1232
  49. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 2006;355:1210–1221
  50. Sugimoto H, Mundel TM, Sund M, Xie L, Cosgrove D, Kalluri R. Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc. Natl. Acad. Sci. U. S. A. 2006;103:7321–7326

PII: S0022-2828(09)00314-9

doi: 10.1016/j.yjmcc.2009.07.022

Journal of Molecular and Cellular Cardiology
Volume 48, Issue 3 , Pages 497-503 , March 2010

Article Tools

* Image Usage & Resolution